News Pharma Industry

Biocon Biologics: IPO and the pandemic on its radar, Biocon Biologics gets a booster shot from Serum Institute

Adar Poonawalla, CEO, Serum Institute of India and Kiran Mazumdar-Shaw, executive chairperson, Biocon announcing the strategic alliance of the companies; image courtesy: Biocon


The deal improves the value proposition of Biocon Biologics by providing a better cash flow outlook and broadened portfolio ahead of the company’s plan to go for an IPO in the next two to three years. While the deal offers Biocon Biologics a perch in a new business, Serum Institute gets a chance to test the waters beyond vaccines.

India’s leading entrepreneurs Kiran Mazumdar-Shaw and Adar Poonawalla struck an unusual but interesting deal last week. Biocon Biologics, the biosimilars arm of Mazumdar-Shaw’s company Biocon, entered into a strategic alliance with Serum Institute Life Sciences Pvt Ltd, a subsidiary of Poonawalla’s Serum Institute of India, to make a foray into vaccines. According to the deal, Biocon Biologics will get access to 100 million doses of vaccines per

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

September Special Offer

Get Flat 20% Off


Get Offer

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link